Market Newsdesk

Investors with losses are encouraged to contact the firm before November 16, 2020; click


here


to submit trade information

LOS ANGELES, Nov. 13, 2020 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Nano-X Imaging, Ltd. (NASDAQ: NNOX) investors that acquired shares between August 21, 2020 and September 15, 2020. Investors have until November 16, 2020 to seek an active role in this litigation.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

A class action lawsuit has been filed in the U.S. District Court for the Eastern District of New York on behalf of those who acquired Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX) securities during the period from August 21, 2020 through September 15, 2020 (the “Class Period”). Investors have until November 16, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Nano-X’s commercial agreements and its customers were fabricated; (2) Nano-X’s statements regarding its “novel” Nano-X System were misleading as the Company never provided data comparing its images with images from competitors’ machines; (3) Nano-X’s submission to the U.S. Food and Drug Administration (“FDA”) admitted the Nano-X System was not original; and (4) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 16, 2020.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising

SHENZHEN, China, Nov. 13, 2020 (GLOBE NEWSWIRE) — Meten EdtechX Education Group Ltd. (NASDAQ: METX) (“Meten EdtechX” or the “Company”), a leading English language training (“ELT”) service provider in China, today announced its online ELT platform， “Likeshuo”， maintained the No. 1 language training sales^[1] among all language training service providers who participated during the “Singles’ Day” nationwide promotion activity on Tmall.com for three consecutive years. Likeshuo generated RMB8.83 million in gross billings during entire 11-days “Singles’ Day” nationwide promotion activity from November 1 to November 11, 2020.

Meten EdtechX launched its online ELT platform, Likeshuo, in 2015 and integrated high-quality online teaching in small-class setting and immersive teaching by foreign teachers from native English-speaking countries. Likeshuo has successively covered English, Japanese, and other minority language training markets. In spite of the COVID-19 epidemic, Likeshuo has achieved a year-on-year growth of more than 30% in gross billings in the first three quarters of 2020 with its strong brand awareness and high-quality teaching services.

^[1] Ranking based on gross billings from November 1 to November 11, 2020

About Meten
 EdtechX

Meten EdtechX is a leading ELT service provider in China, delivering English language and future skills training for Chinese students and professionals. Through a sophisticated digital platform and nationwide network of learning centers, the Company provides its services under three industry-leading brands: Meten (adult and junior ELT services), ABC (primarily junior ELT services) and Likeshuo (online ELT). It offers superior teaching quality and student satisfaction, which are underpinned by cutting edge technology deployed across its business, including AI-driven centralized teaching and management systems that record and analyze learning processes in real time.

The Company is committed to improving the overall English language competence and competitiveness of the Chinese population to keep abreast of the rapid development of globalization. Its experienced management is focused on further developing its digital platform and expanding its network of learning centers to deliver a continually evolving service offerings to a growing number of students across China.

For more information, please visit https://investor.metenedu-edtechx.com.

For investor and media enquiries, please contact:

Meten EdtechX

Wendy Wang

+86 136-5142-6060
wendy_wsr@meten.com

Ascent Investor Relations LLC

Tina Xiao
+1 917-609-0333
[email protected]

BOSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) — The Mass Technology Leadership Council (MassTLC) announced honorees of its Tech Top 50 on a live broadcast on Thursday, November 12. The Tech Top 50 recognizes the region’s tech companies that have made a significant impact in 2020 over five categories: Business Accomplishment, Community Impact, Company Culture, COVID-19 Response, and Innovation.

Over the course of the next few weeks, MassTLC will share the stories of the recipients to spotlight their accomplishments and their impact on customers, partners, employees, and the broader community.

“Despite the challenges we faced in 2020, the Massachusetts tech community remained true to form, demonstrating resilience, strength and an extraordinary capacity for innovation,” remarked MassTLC CEO Tom Hopcroft. “I am excited that MassTLC is able to share these 50 exceptional stories of dedication and innovation this year.”

Tech Top 50 Recipients Include:

The Tech Top 50 is sponsored by Imarc,Invest Northern Ireland,PNC Bank, and PwC.

About
Mass
achusetts
Technology Leadership Council, Inc.

As the largest tech association in the region, the Mass Technology Leadership Council (MassTLC) is the region’s leading technology association and is the premier network for tech executives, entrepreneurs, investors and policy leaders. MassTLC’s purpose is to accelerate an inclusive tech ecosystem by connecting people from across the technology landscape, providing access to industry-leading content and ideas and offering a platform for visibility for member companies and their interests. More at www.masstlc.org.

Contact:
Sara Fraim, MassTLC
[email protected]
781-993-9000

BALA CYNWYD, Pa., Nov. 13, 2020 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, will participate in 1×1 investor meetings at the virtual Guggenheim Securities Healthcare Talks. Additionally, Dr. Ben-Maimon will present a fireside chat and participate in 1×1 investor meetings at the Piper Sandler 32^nd Annual Virtual Healthcare Conference. See below for more details.

Guggenheim Securities Healthcare Talks

Larimar will participate in virtual 1×1 investor meetings on Monday, November 16, 2020.

Piper Sandler 32



^nd



Annual


Virtual


Healthcare Conference

Beginning November 23, 2020, a pre-recorded fireside chat with Dr. Ben-Maimon will be available for viewing anytime through December 3, 2020, by accessing the recording library on the Piper Sandler conference site. Company management will also be participating in virtual 1×1 meetings on December 1 and 3, 2020. Meetings can be requested exclusively via Piper Sandler.

About Larimar Therapeutics

Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for Friedreich’s ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Forward-Looking Statements

This press release contains forward-looking statements that are based on Larimar’s management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar’s ability to develop and commercialize CTI-1601 and other planned product candidates, Larimar’s planned research and development efforts, and other matters regarding Larimar’s business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, the success, cost and timing of Larimar’s product development activities, studies and clinical trials; the ongoing impact of the COVID-19 pandemic on Larimar’s clinical trial timelines, ability to raise additional capital and general economic conditions; Larimar’s ability to optimize and scale CTI-1601’s manufacturing process; Larimar’s ability to obtain regulatory approval for CTI-1601 and future product candidates; Larimar’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; Larimar’s ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made by the Company with the Securities and Exchange Commission (SEC), including but not limited to Larimar’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. These forward-looking statements are based on a combination of facts and factors currently known by Larimar and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent views as of the date hereof. Larimar undertakes no obligation to update any forward-looking statements for any reason, except as required by law.

Investor Contact:

Joyce Allaire
LifeSci Advisors
[email protected]
(212) 915-2569

Media Contact:

Gina Cestari
6 Degrees
[email protected]
(917) 797-7904

–Single and multiple intravitreal injections of NGM621 appeared safe and well tolerated in first-in-human study, with no patients experiencing serious adverse events, drug-related AEs, intraocular inflammation or choroidal neovascularization–

–The serum pharmacokinetics (PK) of NGM621 were linear and dose-proportional–

–NGM621 ocular PK/pharmacodynamics (PD) modeling supports potential for up to every eight-week dosing regimen–

–Enrollment of the CATALINA Phase 2 study of NGM621 in patients with geographic atrophy underway with the first patient dosed in July 2020–

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced that findings from its Phase 1 clinical study of NGM621, an anti-complement C3 antibody, in patients with geographic atrophy (GA) were presented today at the American Academy of Ophthalmology 2020 Virtual. The poster presentation titled, “Inhibition of Complement Component 3 in GA With NGM621: Phase 1 Dose-Escalation Study Results,” was given by the study’s lead investigator Charles C. Wykoff, M.D., Ph.D., Director of Research at Retina Consultants Houston and the Greater Houston Retina Research Foundation. The presentation is available on the NGM Bio website here.

The primary objective of the Phase 1 trial was to assess the safety and tolerability of single and multiple intravitreal (IVT) injections of NGM621 in patients with GA. Secondary objectives were to characterize the serum PK of single or multiple doses of NGM621. The study enrolled 15 patients across three single-ascending dose cohorts of NGM621, 2 mg, 7.5 mg and 15 mg, the maximum planned dose in the study, and a multiple dose cohort that received two 15 mg doses separated by four weeks. Patients were dosed sequentially and followed closely over 12 weeks.

In the study, NGM621 was well tolerated, with no patients experiencing serious adverse events (SAEs), drug-related adverse events (AEs), intraocular inflammation, endophthalmitis or choroidal neovascularization (CNV). No dose-related safety patterns or concerns were reported. Ocular AEs observed were mild in severity and representative of those commonly associated with IVT injections. No vision-related safety signals were detected. On average, patients maintained their visual acuity over the 12-week follow-up study duration.

The serum PK of NGM621 was linear and dose-proportional. Based on ocular PK/PD modeling, NGM621 is predicted to achieve >90% reduction in free C3 in the eye for 7 weeks following a single IVT dose of 15 mg. Taken together, the PK profile of NGM621 demonstrated in the Phase 1 study and subsequent PK/PD modeling support up to an every eight-week (or every other month) dosing regimen of NGM621 at the 15 mg dose level. NGM621 serum exposure was below concentrations expected to produce systemic complement inhibition after IVT injection of the 15 mg dose. No anti-drug antibodies were detected in any patient at any timepoint.

“The findings from this first-in-human study of NGM621 in patients with geographic atrophy give us important insights regarding the potential of this therapeutic to address this progressive and devastating disease,” said Dr. Wykoff. “The favorable safety and tolerability profile seen in this study, combined with the potential for every other month dosing suggest NGM621 may be valuable as a complement C3 inhibitor to treat geographic atrophy. I look forward to continuing to advance our clinical understanding of NGM621 in the ongoing, double-masked Phase 2 CATALINA study.”

GA, an advanced form of age-related macular degeneration, is a progressive retinal degenerative disease associated with irreversible loss of vision, diminished quality of life and eventual blindness. Dysregulated activation of the complement system, a key component of the immune system, has been implicated in the onset and progression of GA. NGM621 is a humanized IgG1 monoclonal antibody engineered to potently inhibit activity of complement C3. It is being tested in the Phase 2 CATALINA trial to evaluate its effects on disease progression when given every four weeks or every eight-weeks.

“We are very pleased to see NGM621’s exciting preclinical data now translating in the clinic as expected. These results support our belief that NGM621 may have a highly differentiated therapeutic profile in the complement inhibition space, and we look forward to building on this body of data with our ongoing Phase 3-enabling CATALINA study,” said Hsiao D. Lieu, M.D., Chief Medical Officer at NGM Bio. “We recognize the difficult and far-reaching impact geographic atrophy can have on patients’ quality of life, and we are committed to advancing this promising therapeutic candidate for these patients.”

More details on the Phase 2 CATALINA study can be found at this link on clinicaltrials.gov.

About NGM621 and Complement C3 Inhibition

NGM621 is a humanized IgG1 monoclonal antibody engineered to potently inhibit complement C3. It is being evaluated with dosing every four weeks and every eight-weeks. NGM621 is not pegylated. In preclinical models, NGM621’s high affinity binding to C3 has demonstrated the potential for potent C3 inhibition. In addition, in well validated animal models of laser-induced choroidal neovascularization (CNV), C3 inhibition has demonstrated the ability to reduce retinal vascular leakage, suggesting the potential for NGM621 to prevent CNV development.

C3 is a key component of the complement system, which helps orchestrate the body’s response to infection and maintains tissue homeostasis. The complement cascade can be activated through its three distinct pathways – classical, lectin and alternative – all of which converge to activate C3. When this cascade is dysregulated, the immune response may lead to the development and progression of GA. Inhibition of C3 represents a promising therapeutic approach that broadly inhibits downstream effector functions triggered by the excessive activation of C3, including inflammation, activation of the adaptive immune system, opsonization (the marking of a pathogen to be destroyed by phagocytes, a type of immune cell), phagocytosis and cell lysis (cell death).

NGM621 was discovered by NGM under its strategic collaboration with Merck.

About NGM Biopharmaceuticals, Inc.

NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying liver and metabolic diseases, retinal diseases and cancer. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs in clinical development. Visit us at www.ngmbio.com for more information.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “potential,” “suggesting,” “look forward,” “advance,” “belief,” “engineered to,” “aspire”, “appeared” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include those related to: the therapeutic potential and profile of NGM621, including the potential to slow the progression of GA, to prevent CNV development and potently inhibit C3, and the potential for up to every eight week dosing of NGM621; the enrollment and potential results of the Phase 2 CATALINA study of NGM621 for the treatment of patients with GA; NGM’s commitment and ability to advance potentially first-in-class and transformative medicines for patients and other statements that are not historical fact. Because such statements deal with future events and are based on NGM’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of NGM could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, the risk that NGM’s ongoing or future clinical studies in humans may show that NGM621 is not a tolerable and effective treatment for geographic atrophy or that every eight week dosing with NGM621 is not possible and other risks and uncertainties affecting NGM and its development programs, as well as those discussed in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in NGM’s quarterly report on Form 10-Q for the quarter ended September 30, 2020 and future filings and reports that NGM makes from time to time with the United States Securities and Exchange Commission. Except as required by law, NGM assumes no obligation to update these forward-looking statements or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.